Physician profile
Marlene Yacoob
NPI 1568480218
$17,499.03
in general payments reported to CMS, 2019-2025
72 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $2,231 · 2021: $3,639 · 2022: $2,916 · 2023: $2,430 · 2024: $2,268 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,030.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,681.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $2,337.89 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Novo Nordisk INC | $1,673.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,329.13 | 2020-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $953.92 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $885.13 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $791.93 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $695.97 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $438.41 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $413.80 | 2021-2025 | |
| Pfizer INC. | $399.93 | 2019-2025 | |
| Esperion Therapeutics, INC. | $249.96 | 2021-2025 | Nexletol |
| Abbott Laboratories | $240.56 | 2019-2024 | Eterna, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $233.52 | 2019-2022 | |
| Amarin Pharma, INC. | $228.18 | 2019-2022 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Yacoob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.